A Phase 2 interventional study of bevacizumab [Avastin] and temozolomide in Glioblastoma Multiforme, sponsored by Hoffmann-La Roche. Completed at 8 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-08.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.
Among the 232 studies testing temozolomide in Glioblastoma, this one is the 128th largest by enrollment of the 221 interventional ones that give a count, is one of 11 that started in 2010, is one of 99 in phase 2, and was the 105th registered.
2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.
Browse Glioblastoma studies →25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 16+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
Rigel Pharmaceuticals · Sites in United States, Australia, Canada and 4 more countries
Ages 12–39
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 110 · Phase 2 140 · Phase 3 16 · Phase 4 2
First in 1997; this study’s year is marked. 11 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 41 across the 221 interventional studies. Of the 168 that completed or were terminated, 69 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 232 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
13 studies in Glioblastoma by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 13 finished, 4 (31%) have results posted.
Among the 13 studies in Glioblastoma by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 5th registered.
Hoffmann-La Roche’s Glioblastoma studies by the year they started, since 2003.
5 of the studies testing temozolomide in Glioblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT04019262John FlickingerShort Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | 2026-12 |
| NCT04623931M.D. Anderson Cancer CenterChemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | 2026-12-31 |
| NCT07193654Second Affiliated Hospital, School of Medicine, Zhejiang UniversityStupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | 2027-04-01 |
| NCT06297512Iacopo SardiEvaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | 2027-11-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 232 studies testing temozolomide in Glioblastoma, from their registry updates:
Among Hoffmann-La Roche’s 13 in Glioblastoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase II, national, multicenter, open-label, non-comparative study to investigate the efficacy and safety of bevacizumab and temozolomide in patients with recurrent glioblastoma multiforme (GBM) after a first treatment failure. Patients will receive bevacizumab 10 mg/kg intravenously every two weeks until disease progression, consent withdrawal, or unacceptable toxicity. Anticipated time on study treatment is 12-24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: temozolomide
Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
Progression-Free Survival (PFS) - Percentage of Participants With an Event
PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment.
Time frame: Baseline (BL), every 28 days, until progression, death or end-of-study, an average of 32 weeks
PFS - Time to Event
PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment. PFS was estimated using the Kaplan-Meier method.
Time frame: BL, every 28 days, until progression, death or end-of-study, an average of 32 weeks
PFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study
Time frame: BL, 24 weeks (after 6th cycle)
Overall Survival - Percentage of Participants With an Event
Overall survival was defined as the time transpired (in weeks) between the date of the participant's inclusion in the trial until the date of his/her death by any cause. Participants that were alive at the time the analysis was performed were censored on the date of last contact.
Time frame: BL, every 28 days, until death or end-of-study, an average of 32 weeks
Overall Survival - Time to Event
Overall survival was defined as the time transpired (in weeks) between the date of the participant's inclusion in the trial until the date of his/her death by any cause. Participants that were alive at the time the analysis was performed were censored on the date of last contact. Median overall survival was estimated using the Kaplan-Meier method.
Time frame: BL, every 28 days, until death or end-of-study, an average of 32 weeks
Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)
Overall response was defined as the percentage of participants who obtained CR or PR using adapted MacDonald criteria. CR: disappearance of all index and non-index lesions, confirmed no less than 4 weeks after assessment, no evidence of disease progression; corticosteroid dosage at or below 20 mg hydrocortisone daily; no neurological changes or an improvement as compared to last disease assessment. PR was defined as: Fifty percent or greater decrease in the sum of products of the larger diameter and the larger perpendicular diameter of all index lesions confirmed no less than 4 weeks after assessment, no evidence of disease progression and the absence of progressive, or non-evaluable disease status for non-index legions; unchanged, or decreased corticosteroid dose as compared to the last disease assessment; no neurological changes or an improvement as compared to the neurological examination at last disease assessment.
Time frame: BL, every 28 days, until progression, death or end-of-study, an average of 32 weeks
| Milestone | Bevacizumab + Temozolomide |
|---|---|
| Started | 32 |
| Completed | 2 |
| Not completed | 30 |
| Withdrew: Death | 22 |
| Withdrew: Adverse event | 3 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 1 |
PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment.
| percentage of participants | Bevacizumab + Temozolomide |
|---|---|
| Progression-Free Survival (PFS) - Percentage of Participants With an Event | 96.88 |
PFS was defined as the time, in weeks, from the date of inclusion in the study to the date of the first documentation of disease progression or death of the participant due to any cause. Participants that did not have an event at the time the analysis was performed were censored at the date of last contact. Participants that began a treatment other than those planned in this study (bevacizumab or temozolomide) were censored on the start date of the new treatment. PFS was estimated using the Kaplan-Meier method.
| weeks | Bevacizumab + Temozolomide |
|---|---|
| PFS - Time to Event | 18.29 (15.43 to 23.57) |
Overall survival was defined as the time transpired (in weeks) between the date of the participant's inclusion in the trial until the date of his/her death by any cause. Participants that were alive at the time the analysis was performed were censored on the date of last contact.
| percentage of participants | Bevacizumab + Temozolomide |
|---|---|
| Overall Survival - Percentage of Participants With an Event | 75.00 |
Overall survival was defined as the time transpired (in weeks) between the date of the participant's inclusion in the trial until the date of his/her death by any cause. Participants that were alive at the time the analysis was performed were censored on the date of last contact. Median overall survival was estimated using the Kaplan-Meier method.
| weeks | Bevacizumab + Temozolomide |
|---|---|
| Overall Survival - Time to Event | 31.43 (25.14 to 38.29) |
| survival probability | Bevacizumab + Temozolomide |
|---|---|
| PFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study | 0.30000 ± 0.0819 |
Overall response was defined as the percentage of participants who obtained CR or PR using adapted MacDonald criteria. CR: disappearance of all index and non-index lesions, confirmed no less than 4 weeks after assessment, no evidence of disease progression; corticosteroid dosage at or below 20 mg hydrocortisone daily; no neurological changes or an improvement as compared to last disease assessment. PR was defined as: Fifty percent or greater decrease in the sum of products of the larger diameter and the larger perpendicular diameter of all index lesions confirmed no less than 4 weeks after assessment, no evidence of disease progression and the absence of progressive, or non-evaluable disease status for non-index legions; unchanged, or decreased corticosteroid dose as compared to the last disease assessment; no neurological changes or an improvement as compared to the neurological examination at last disease assessment.
| percentage of participants | Bevacizumab + Temozolomide |
|---|---|
| Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR) | 40.6 |
Collected over Adverse events (AEs) were collected from the date of start of study treatment to 90 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + Temozolomide | — | 8/32 (25%) | 32/32 (100%) |
| Event | Bevacizumab + Temozolomide |
|---|---|
| Lung (pneumonia)Infections and infestations | 2/32 |
| FeverGeneral disorders | 2/32 |
| Upper respiratory tract infectionInfections and infestations | 1/32 |
| Neurological disorder NOSNervous system disorders | 1/32 |
| SeizuresNervous system disorders | 1/32 |
| ThrombosisVascular disorders | 1/32 |
| Bladder haemorrhageRenal and urinary disorders | 1/32 |
| Intracranial haemorrhageBlood and lymphatic system disorders | 1/32 |
| Back painMusculoskeletal and connective tissue disorders | 1/32 |
| Event | Bevacizumab + Temozolomide |
|---|---|
| FatigueGeneral disorders | 18/32 |
| Lymphocyte count decreasedBlood and lymphatic system disorders | 16/32 |
| Platelet count decreasedBlood and lymphatic system disorders | 15/32 |
| NauseaGastrointestinal disorders | 11/32 |
| Olfactory nerve disorderNervous system disorders | 9/32 |
| HeadacheNervous system disorders | 9/32 |
| AnorexiaMetabolism and nutrition disorders | 8/32 |
| Upper respiratory infectionInfections and infestations | 8/32 |
| HypertensionVascular disorders | 7/32 |
| Neutrophil count decreasedBlood and lymphatic system disorders | 6/32 |
Intent-to-treat (ITT) population: all enrolled participants.
| Age, Continuous(years) | Bevacizumab + Temozolomide |
|---|---|
| Mean | 56.19 ± 10.58 |
| Sex: Female, Male(Participants) | Bevacizumab + Temozolomide |
|---|---|
| Female | 15 |
| Male | 17 |
The record gives a start of Jun 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Temozolomide